

Biofilm management protocol

Cadexomer iodine (IODOSORB[®]) is indicated for the management of sloughy and non-healing chronic ulcers such as diabetes-related foot ulcers, venous leg ulcers, pressure injuries and other wounds healing by secondary intention.

IODOSORB has several modes of action:



1. Disrupts biofilm¹⁻⁴



2. Reduces bioburden^{1,5-7}



3. Absorbs exudate^{5,8-12}



4. Removes slough & necrotic tissue^{5,8-10}

Clean wound as per local protocol

Apply Cadexomer Iodine (IODOSORB) to wound:

Ointment

- Apply ointment, making sure there is enough to cover whole wound with 3mm depth
- Use glove to spread out Cadexomer Iodine (IODOSORB) to ensure coverage of whole wound
- Cover with secondary dressing. If wound is heavily exuding use foam dressing



Powder

- Apply cadexomer iodine (IODOSORB) to surface of wound to depth of at least 3mm.
- Cover with secondary dressing. If wound is heavily exuding use foam dressing



Change Cadexomer Iodine (IODOSORB) every 2-3 days OR when colour has changed.

- If necessary soak dressing for several minutes with saline to loosen.
- Remove using stream of sterile water or saline



Reassess after two weeks

- If wound has started healing, but slough still present, continue Cadexomer Iodine (IODOSORB use) for a further two weeks, then reassess.

- If no apparent healing, discontinue and reassess patient to ensure correct diagnosis and all comorbidities controlled.

- If clean granulation tissue is present change to appropriate non-antimicrobial dressing (e.g. foam). If risk of further infection persists, consider the use of nanocrystalline silver (ACTICOAT[™]) to prevent biofilm reforming.

References

1. Phillips PL, et al. Antimicrobial dressing efficacy against mature Pseudomonas aeruginosa biofilm on porcine skin explants. Int Wound J 2015; 12: 469–483.
2. Akiyama H, et al. Assessment of cadexomer iodine against Staphylococcus aureus biofilm in vivo and in vitro using confocal laser scanning microscopy. J Dermatol 2004; 31:529-534.
3. Lumb H. Testing the biofilm disruption activity of IODOFLEX dressing. Data on file; 2007: report TSG015-07-001 V2.
4. Lumb H. Testing the biofilm prevention activity of IODOFLEX dressing. Data on file; 2007: report TSG015-07-001.
5. Sundberg J, Meller R. A retrospective review of the use of cadexomer iodine in the treatment of wounds. Wounds 1997; 9(3): 68-86.
6. Salman H, Leakey A. The in vitro activity of silver sulphadiazine and cadexomer iodine against recent clinical isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant coagulase-negative Staphylococci and Pseudomonas aeruginosa. Data on file; 2001: report 194-03-01.
7. Zhou LH, et al. Slow release iodine preparation and wound healing: in vitro effects consistent with lack of in vivo toxicity in human chronic wounds. Brit J Derm 2002;146: 365-374.
8. Troeng T, et al. A randomized multicenter trial to compare the efficacy of cadexomer iodine and standard treatment in the management of chronic venous ulcers in out-patients. In: Fox JA, Fischer H, eds. Cadexomer Iodine. New York: F.K. Schattauer Verlag; 1983:43-50.
9. Ormiston MC, et al. Controlled trial of Iodosorb in chronic venous ulcers. BMJ 1985; 291: 308-310.
10. Hansson C, et al. The effects of cadexomer iodine paste in the treatment of venous ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Int J Dermatol 1998; 37: 390-396.
11. Lindsay G, et al. A study in general practice of the efficacy of cadexomer iodine in venous leg ulcers treated on alternative days. Acta Therapeutica 1986; 12:141-147.
12. Skog E, et al. A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers. Brit J Derm 1983; 109: 77-83.